The renal allograft biopsy  by Colvin, Robert B.
Kidney International, Vol. 50 (1996), pp. 1069—1082
The renal allograft biopsy
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A 43-year-old man was admitted to the Massachusetts General Hospital
(MGH) for a renal biopsy to evaluate a rising creatinine and the new onset
of nephrotic-range proteinuria 2 years after receiving a cadaveric renal
allograft at the MGH.
The patient, an insulin-dependent diabetic since age 18, had developed
renal failure, hypertension, and retinopathy. The patient's nephrectomy
specimen showed end-stage nodular diabetic glomerulosclerosis. The
patient received immunosuppressive treatment with cyclosporine A
(CsA), azathioprine, and prednisone after transplantation.
The allograft functioned well initially; the serum creatinine level fell to
1.6 mgldl on day 6 but rose to 2.3 mg/dl on day 11. The blood CsA level
was 511 ng/ml. A renal biopsy showed hyaline deposits in small arteries
and mild interstitial fibrosis. Four glomeruli were unremarkable. No
infiltrate or tubular injury was evident. The dose of CsA was reduced and
the serum creatinine declined, stabilizing at a baseline of 1.5 mg/dl to 1.8
mg/dl over the next 18 months.
About 6 months prior to admission, his serum creatinine began rising
slowly, from 2.0 mg/dl to 4.1 mg/dl, and proteinuria began to increase,
from 1.1 to 5.3 g/day. He was admitted to the hospital for a renal biopsy
to assess the potential for reversing the process. On admission his blood
pressure was 150/80 mm Hg; the renal transplant was not swollen or
tender. His CsA level was 212 ng/ml and his serum creatinine concentra-
tion was 4.5 mg/dl.
A percutaneous renal gun biopsy performed with a 15-gauge needle
yielded cortex with 13 glomeruli. Many of the glomeruli had collapsed
tufts, with enlarged, basophilic podocytes; one had segmental sclerosis and
2 had global sclerosis. The arterioles had marked hyaline deposition, and
the small arteries had intimal fibrosis. Prominent interstitial fibrosis,
tubular atrophy, and focal collections of mononuclear cells were present.
Immunofluorescent evaluation showed 1gM and C3 (1+ to 4+) in a broad
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granular pattern in glomeruli; other stains were negative. Electron micros-
copy showed effacement of foot processes and microvillous changes in
podocytes. The glomerular basement membrane was normal in thickness;
no deposits were evident.
Discussion
DR. ROBERT B. COLVIN (Chief Department of Pathology, Mas-
sachusetts General Hospital, and Benjamin Castleman Professor of
Pathology, Harvard Medical School, Boston, Massachusetts, USA):
Let me begin with a brief comment on this case. The first allograft
biopsy showed donor vascular disease but no evidence of rejec-
tion. The lack of tubular and vascular changes was consistent with
mild CsA toxicity. Accordingly, the CsA dose was reduced with
beneficial results. The second biopsy also showed no evidence of
active rejection. The vascular lesions had progressed and can be
attributed to a combination of donor nephrosclerosis plus recur-
rent diabetic arteriopathy. The hyaline deposits were not diagnos-
tic of chronic CsA toxicity, in which the hyaline replaces individual
smooth muscles. The glomerular lesions are distinctive and typical
of the collapsing variant of focal sclerosis, a process not known to
be part of chronic rejection. I will return to the significance of this
process later. In this Forum, I will update the current status of the
renal biopsy in assessing renal allograft dysfunction, based on my
prior review [1]. I will review classification, pathogenesis, diagnos-
tic criteria, and differential diagnosis of allograft rejection and
CsA toxicity.
As I stated previously, the renal biopsy remains the most
definitive and reliable diagnostic test for graft rejection [11. The
biopsy is more sensitive and more specific than radionuclide
scintigraphy, fine-needle aspiration, or ultrasound [2]. Studies
show that results of allograft biopsy can change the clinical
diagnosis and/or treatment in approximately 40% of patients and
spare these patients the risk and expense of unnecessary immu-
nosuppression [3—51. Fortunately, percutaneous allograft biopsy is
a safe procedure; in two large series totaling 1390 biopsies,
percutaneous biopsy caused no deaths and only 0.3% to 0.4%
graft loss [4, 6]. The graft losses were restricted to patients with
severe acute rejection [6]. With the "gun" biopsy, the preferred
method at the Massachusetts General Hospital currently, no graft
loss or deaths have occurred in 1421 procedures [7].
Classification. As Hamburger pointed out 30 years ago, graft
rejection cannot be attributed merely to different intensities of a
single type of immune response [8]. The ideal diagnostic classifi-
cation should be based on pathogenesis, have therapeutic rele-
vance, and be reproducible. Using published data and my own
experience, I have attempted to classify graft rejection according
to these criteria (Table 1).
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Table 1. Renal allograft pathology: diagnostic categories"
Immunologic rgjycfion
Antibody mediated
Hyperacute allograft rejection
Acute humoral rejection/thrombotic vasculopathy
Necrotizing arteritis (may have T-ccll component)
De-novo mcmbranous glomerulonephritis
Immune response to normal renal antigens
Anti-GBM disease in Alport's syndrome
Anti-TBM disease (? alloantigen)
T-cell mediated
Acute cellular allograft rejection
Tubulo-interstitial
Vascular (endothelialitis)
Glomerular (acute allograft glomerulopathy)
Mixed or unknown pathogenesis
Chronic allograft rejection
Tubulo-interstitial
Vascular (accelerated artherosclerosis)
Glomerular (chronic allograft
glomerulopathy)
Non-rejection injury
Acute ischemic injury (ATN)
Perfusion injury
Cyclosporinc A nephrotoxicity
Acute cyclosporine A toxicity
Tubular
Vascular
Medial necrosis
Hemolytic-uremic syndrome
Chronic cyclosporine A toxicity
Tubulo-interstitial
Vascular (hyalinosis)
Tacrolimus (FK506) toxicity
Tubular
Vascular
? Focal glomerular sclerosis
OKT3 toxicity
Thrombotic angiopathy
Major vessel occlusion/stenosis
Obstruction
Infection
Acute interstitial nephritis (drug allergy)
De-novo glomerular sclerosis
Focal glomerular sclerosis
Diabetic nephropathy
Post-transplant lymphoproliferative disease
Recurrent orimary disease
Immunologic
Metabolic
Reprinted with permission from Raven Press [1].
Two working groups have recently proposed criteria for a
numerical score for grading acute renal allograft rejection. Both
groups defined the threshold for the diagnosis of rejection based
on their pathology expertise without proving the clinical rele-
vance. In the "Banif" classification developed by Solez and
collaborators, 5 grades (borderline to grade 3 with subgrades) are
recognized, with detailed scoring of the degree of infiltrate,
tubulitis, endothelialitis, and glomerular lesions 191. The threshold
between "borderline" and "grade-i" rejection arbitrarily was
defined as the presence of tubulitis with ">4 mononuclear
cells/tubular cross section or group of 10 tubular cells and >25%
interstitial infiltration." The Banif system is complex, but it has the
Table 2. NIH-CdT classification of acute renal allograft rejection
Type 1. Mononuclear infiltrate in >5% of cortex, at least 3 tubules
with tubulitis in 10 consecutive high-power fields from the most
severely affected areas, and at least 2 of the 3 following
features: edema, activated lymphocytes, or tubular injury.
Type 2. Arterial or arteriolar endothelialitis, with or without type-I
features.
Type 3. Arterial fibrinoid necrosis or transmural inflammation, with or
without thrombosis, parenchymal necrosis, or hemorrhage.
advantage for clinical trials that each element of rejection is
recorded and scored.
A simplified scoring system for renal allograft biopsies recently
has been developed by a panel of renal pathologists participating
in the Cooperative Clinical Trials in Transplantation (CCTT), an
NIH-supported, eight-center research group evaluating novel
immunosuppressive strategies (Colvin R, et al, unpublished data).
The panel reached a consensus on the definition of three catego-
ries of acute cellular rejection (Table 2). Using these criteria, and
without having any knowledge of the clinical course or original
diagnosis, a panel of three pathologists agreed with the original
pathologist's diagnosis of rejection or non-rejection in more than
90% of the cases. The panel found the system useful and practical,
noting that it was similar to their standard approach to diagnosis
and classification of rejection.
The development of these systems has promoted clearer defi-
nitions and agreement among renal pathologists. These schema
probably will evolve and classification criteria will be refined as
studies identify their clinical relevance. I believe that the diagnos-
tic categories should be no more complex than pathogenetic,
prognostic, or therapeutic distinctions require. Telepathology,
recently tested in Japan, provides a means of rapid consultation
with distant experts and also can promote more uniformity in
diagnosis [10].
Diagnostic approach. The H & E and PAS stained sections are
carefully examined for (1) the nature and degree of the interstitial
infiltrate (for example, activated mononuclear cells, edema); (2)
vascular lesions (for example, endothelialitis, myocyte necrosis,
thrombi); (3) tubular injury and inflammation (tubulitis); and (4)
glomerular lesions. Further sections are obtained if no diagnosis is
evident. We use a standard immunofluorescence panel of IgG,
IgA, 1gM, C3, albumin, and fibrin. Electron microscopy is used
when de-novo or recurrent glomerular disease is suspected.
Immunoperoxidase staining is helpful when the differential diag-
nosis includes lymphoproliferative or viral disease. Criteria for
judging the adequacy of the sample depend on the lesions seen;
one artery with endothelialitis is sufficient for the diagnosis of
acute rejection, even if no glomerulus is present; similarly, immu-
nofluorescence or electron microscopy of one glomerulus is
adequate for diagnosing de-novo membranous glomerulonephri-•
tis. In contrast, a portion of cortex with a minimal infiltrate does
not exclude rejection, even with 20 glomeruli. Examination of
medulla alone is not sufficient to diagnose or rule out rejection (6].
Most suhcapsular biopsy specimens show inflammation and fibro-
sis and thus are not helpful.
Frozen sections are of limited value, hut they can be utilized in
urgent situations. Frozen sections do reveal cellular infiltrates and
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occasionally endothelialitis; cortical necrosis and hyperacute re-
jection are also obvious. Tubulitis and thrombi are less easily
found. Most glomerular lesions are difficult to assess on frozen
section, although crescents are unambiguous. Overall, the diag-
nostic accuracy of frozen sections in one rigorous study of 69
transplant biopsies was 89% [11]. Errors included overlooking
acute cellular rejection due to sampling, and not detecting micro-
thrombi, vascular inflammation, or glomerular lesions. Rapid
(2-hour) permanent sections currently are being evaluated in our
laboratory as an alternative to frozen sections.
Biopsy of the donor kidney sometimes is used to determine the
suitability of the kidney for transplantation. Only 38% of 147
cadaver donor biopsies were entirely normal at the time of
transplantation [12]. The abnormalities included intravascular
coagulation (7%), interstitial fibrosis (8%), and arteriolar hyali-
nosis (29%); 75% of the biopsies showed IgM/C3 deposits in
glomeruli and/or arterioles, 5% had glomerular IgA deposits, and
3% had glomerulosclerosis. Somewhat surprisingly, the initial and
late renal function of the graft were independent of these
morphologic findings. The presence of arteriosclerotic lesions was
associated with a small but significant difference in 2-year graft
survival in another large series (66% versus 72%) [13]. However,
a recent study has reported that the presence of 20% glomerular
sclerosis in donor biopsy specimens from donors over age 50
strongly correlates with loss of the graft; 38% of such grafts were
lost compared to only 7% lost when the donor biopsy showed less
sclerosis [14]. Specific criteria for accepting donor kidneys with
these morphologic abnormalities need to be established.
Biopsies of the reperfused donor kidney were once fashionable
for predicting the likelihood of rejection. A recent analysis
concluded that neutrophils in glomeruli alone correlated with cold
ischemic time and subsequent graft loss [15]. Increased neutro-
phils in peritubular capillaries, if also in glomeruli, always indi-
cated hyperacute rejection. Unexpectedly, neutrophils in peritu-
bular capillaries alone predicted subsequent cellular rejection.
Glomerular thrombosis and tubular casts were related to preser-
vation but had no correlation with outcome [15].
Antibody-mediated rejection. Hyperacute rejection is caused by
binding of circulating antibodies to the surface of endothelial
cells, complement fixation, platelet activation, lysis of the endo-
thelium, and activation of the clotting system with thrombosis.
The endothelium is stripped off the underlying basal lamina, and
the interstitium becomes edematous and hemorrhagic. Immediate
(1 hour) biopsy of the reperfused allograft usually shows neutro-
phils in peritubular capillaries and glomeruli. Intravascular coag-
ulation occurs and cortical necrosis ensues over 12 to 24 hours
without evidence of mononuclear cell participation; the medulla is
relatively spared. Immunofluorescent examination typically shows
immunoglobulin (especially 1gM) and complement components in
the vascular and glomerular lesions. Antibody sometimes cannot
be detected in the tissues, presumably because the endothelial
cells have disintegrated and the membrane-bound antibody has
been washed away or degraded.
The target antigens are ABO blood group antigens, HLA
class-I or rarely class-IT antigens. Cold agglutinins, especially
those reactive at 22"C, also can cause immediate graft dysfunction
due to intravascular aggregation and thrombosis and have been
implicated in immediate injury in kidneys that are not rewarmed
before blood flow is re-established [16]. The lesions, which have
relatively few neutrophils, resemble ex-vivo perfusion injury.
Hyperacute rejection fortunately is preventable and rare, encoun-
tered in fewer than 0.2% of transplants currently.
A delayed form of rejection with prominent neutrophils and
fibrin thrombi in the peritubular capillaries and glomeruli has
been associated with anti-HLA class-I antibodies in the first three
months post transplant [17]. This lesion has relatively little
tubulitis, interstitial infiltration, or activated mononuclear cells; a
T-celI-mediated mechanism for its pathogenesis is therefore un-
likely. In some cases, arterial and arteriolar thrombosis and
glomerular thrombosis and necrosis predominate, similar to
thrombotic microangiopathy [18]. These lesions must be distin-
guished from the hemolytic-uremic syndrome of CsA toxicity,
which also can have thrombi in arterioles and glomeruli, but which
does not affect the peritubular capillaries. The prognosis is poor,
with only 50% recovery in one series [18] and 62% in another [17],
compared with 96% recovery for acute cellular rejection. The
authors concluded that patients with antibody against donor
class-I antigens had more severe rejection, probably because
anti-class-I antibodies injure the endothelium of small blood
vessels of the graft and lead to rapid functional deterioration [17].
Necrotizing arteritis, also known as "accelerated" or "vascular"
rejection, was commonly recognized in the early studies of
allografts, occurring in 7% of biopsies in the pre-CsA era [19].
Fortunately, it is now seen in less than 1% of allograft biopsy
specimens. The arterial media shows myocyte necrosis, fragmen-
tation of elastica, and accumulation of brightly eosinophilic
material called "fibrinoid," and little mononuclear infiltrate in the
intima or adventitia. A scant infiltrate of neutrophils and eosino-
phils and thrombosis may be present. Immunofluorescent exam-
ination reveals that the "fibrinoid" deposits contain immunoglob-
ulin (usually IgG and 1gM), C3, and fibrin. This lesion appears
similar to microscopic polyarteritis. It can arise at any time,
although usually in the first six weeks, and can occur even in
HLA-identical grafts. This lesion can develop rapidly in presen-
sitized recipients, and it appears to be mediated primarily by
humoral antibody. A T-cell component is suggested by the rare
case that responds to OKT3 therapy [201. The prognosis is
uniformly poor, about 75% graft loss at one year [19, 20].
T-cell-mediated rejection. Acute cellular rejection, the most
common form of rejection, classically develops one to six weeks
after transplantation, but it can occur at any time, even after many
years. The sites of acute cellular rejection—the interstitium,
tubules, endothelium, and glomeruli— can be involved separately
or in combination. The characteristic microscopic feature is a
pleiomorphic interstitial infiltrate of mononuclear cells, accompa-
nied by interstitial edema and a variable amount of hemorrhage.
The cells invade tubules and commonly infiltrate endothelium at
all levels, most obviously the arterioles and small arteries.
The infiltrating mononuclear cells typically include lympho-
blasts, with cytoplasmic basophilia, nucleoli, and occasional mi-
totic figures, which are indicative of increased synthetic and
proliferative activity. Typically 30% to 50% of infiltrating cells are
CD3 T-cells [22—24]. CD8 cells usually predominate and
infiltrate diffusely in the renal cortex [23, 24]. CD4 cells are more
numerous in perivascular aggregates, especially in early biopsies
[23, 24]. Activation markers expressed by the infiltrating T-cells
include the IL-2 receptor [25], transferrin receptor [3], HLA
DR/DO [3, 22, 24], and CD38 [22]. The T-cells in the infiltrate
express the CD45RO isoform of activated/memory cells [26], and
1072 Nephrology Fonim: The renal allograft biopsy
the ratio of CD45RO!RA is increased in rejection, particularly in
the diffuse peritubular infiltrate [27]. Perform, a pore-forming
effector molecule of cytotoxic T-cells, is detectable in a minority of
the cells in acute rejection, and reportedly is more prevalent in
irreversible rejection [28]. TIA-1, a molecule in cytotoxic T-cells
that triggers apoptosis in target cells, is expressed by more than
90% of the CD8 infiltrate (Meehan S, et a!, unpublished data).
Macrophages are often the predominant leukocyte [29, 30];
other cells include minor fractions of granulocytes and natural
killer (NK) cells. Basophils and eosinophils rarely comprise more
than 2% to 3% of the infiltrate [31, 32]; neutrophils can be focally
prominent and occasionally form intratubular casts that mimic
acute pyelonephritis. Immunofluorescence microscopy shows lit-
tle, if any, immunoglobulin deposition, but interstitial fibrin,
fibronectin, and tenascin typically are present [33].
Cytokine production has been documented by in-situ hybrid-
ization and polymerase chain reaction (PCR). Both TNFa and
IFN7 proteins are present in the cells in acutely rejecting human
renal allografts at 5 to 10 times the frequency of that in non-
rejecting grafts (in which about 1 cell/mm2 is positive) [34]. TNFa
mRNA is restricted to the mononuclear cell infiltrate, especially
at the corticomedullary junction; the TNFa protein is antigeni-
cally detectable in glomerular endothelial cells and tubules [35].
TNFI3 (lymphotoxin)-containing mononuclear cells were found in
all cases of acute rejection [36]. One study reports that cells with
mRNA for IL-2, -3, -4 or IFNy are detectable by in-situ hybrid-
ization in fewer than 50% of acute rejection biopsy specimens and
even when present are found in less than 1 cell/high-power field
[37]; perhaps this low frequency reflects the timing of the sample
or the sensitivity of the technique. Additional cytokines that have
been detected by PCR are IL-4, IL-5, and IL-6 [38]. In a
comprehensive study by carefully standardized reverse transcrip-
tion (RT)-PCR, clinically stable grafts had similar levels of IL-2,
IL-2 receptor, IL-i, and IL-6 compared with rejecting grafts; the
only difference found was in the mRNA levels of proteins related
to cytotoxic effector cells, such as granzyme B and TIA-1 [39, 40].
These data strongly argue that the cytotoxic response is respon-
sible for clinically evident acute graft injury. More clinicopatho-
logic analysis will be needed to resolve the important pathogenetic
and diagnostic features of cytokine production.
Mononuclear cells commonly invade tubules and insinuate
between tubular epithelial cells. Both proximal and distal tubules
are affected, particularly the distal convoluted segments [411;
CD8 and CD4 cells invade tubules to a similar degree,
suggesting that both class-I and -II antigens are targets [241. It is
not known what attracts the lymphocytes into the tubule, although
a likely candidate is IL-8, which is chemotactic for lymphocytes
and neutrophils. Ir acute cellular rejection, proximal and distal
tubules stain for IL-8, and tubular cells make IL-8 in culture in
response to IL-i and TNFa [42]. RANTES (a cytokine chemo-
tactic for T-cells, monocytes, and eosinophils) is made by tubular
epithelial cells in rejection [31. "Tubulitis" occurs in other forms
of acute interstitial nephritis, such as drug-induced allergic inter-
stitial nephritis.
Increased expression of DR and adhesion molecules is charac-
teristic of acute cellular rejection. Increased tubular DR antigen
expression correlates strongly with the presence of a T-cell
infiltrate and presumably is a local response to IFNy produced by
these cells [22, 44]. The IFNy receptor is detectable in proximal
and distal tubules in acute rejection [341. Quantitative grading of
tubular DR has permitted the diagnosis of 94% of rejection
episodes, with no false positives among those with CsA toxicity or
stable function [45]. However, DR lingers after upregulation and
is not by itself sufficient to indicate rejection activity. ICAM-1
(CD54) is also increased during rejection on tubular epithelium,
especially the brush border of proximal tubules [46—49]. The
expression is closely correlated with DR, but both are found in
grafts that do not show histologic evidence of rejection [46].
VCAM-1 is also increased, more on the basal surface of tubular
cells [471, and correlates with activated T-cell infiltrates [29, 48].
Endarteritis is a common and significant manifestation of
cellular rejection. Such lesions have been observed in all allograft
organs, although they are most readily detected in the kidney,
which has the most extensive arterial and arteriolar bed. Infiltra-
tion of mononuclear cells under arterial and arteriolar endothe-
hum is the pathognomonic lesion of acute cellular rejection.
When lymphocytes are only on the surface of the endothelium,
their significance is less certain. Nevertheless, we regard mono-
nuclear cells attached to the endothehium as "highly suggestive" of
active cellular rejection. Lymphocytes also commonly surround
vessels, a nonspecific feature, unless the cells invade the media.
The peritubular capillaries are also a target of injury, as judged
morphologically and by the loss of endothelial markers such as
HLA-DR [50] and endothelin [51] during acute rejection. Endo-
theliahitis has been reported in 48% of the renal biopsies with
acute cellular rejection in two series [52, 53]; this percentage
conforms with my experience. Some pathologists do not find the
lesion as often, possibly because of inadequate sampling, overdi-
agnosis of rejection, or the timing of the biopsy with respect to
anti-rejection therapy. These vascular lesions can be most prom-
inent in the arcuate-sized arteries.
The evidence is convincing that acute cellular endarteritis is
mediated by T-cehls rather than by antibodies. T-cells and not
antibody are in the lesion. The inflammatory cells associated with
the endothelium include lymphocytes, lymphoblasts, and mono-
cytes, but seldom granulocytes. The cellular arteritis occurs in the
absence of humoral antibody and has not been produced by
passive transfer of antibodies in animals. Finally, in humans,
rejection with vascular infiltrates usually can be reversed with
OKT3 [20, 53, 54].
The endothelial cells are typically reactive, as manifested by
increased cytoplasmic volume and basophilia. They can be lifted
off the subendothelial basement membrane and can be diffIcult to
distinguish from artifact unless mononuclear cells undermine
them. Or they can be necrotic or absent. The media usually shows
little change. Frank necrosis of the wall or thrombosis is unusual.
Both CD8 and CD4 cells invade the intima in early grafts, but
later CD8 cells predominate [24]; class-I antigens thus are likely
the primary target. Immunofluorescence studies sometimes show
focal fibrin deposition, but little or no immunoglobulin. HLA-DR
is increased during rejection in the endothehium of larger vessels,
which normally has little or no class-Il antigen [55]. Arterial
endothelium shows increased ICAM-1 and VCAM-1 in acute
rejection [46, 47, 49, 561. Arterial VCAM-l was limited to sites of
endothehialitis and also was evident in the arterial smooth muscle
cells [561. ICAM-1 and VCAM-l augment T-cell antigen recog-
nition and monocyte adhesion, potentially promoting rejection.
The adhesion molecule P-selectiri remains unchanged, and E-
selectin is variably increased [47—49]. Increased expression of
MHC antigen and adhesion molecules is believed to be a response
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to cytokines. Tissue necrosis factor receptors are detectable in the
endothelium of arteries during rejection [36]. RANTES is also
synthesized by vascular endothelium in rejection [431.
Endarteritis (that is, cellular arteritis) must not be confused
with necrotizing arteritis, a lesion characteristic of accelerated
rejection and probably due to humoral antibody (see earlier), or
the thrombotic vasculopathy sometimes seen. Rarely, the severity
of the cellular inflammation causes frank medial necrosis, but this
complication of cellular arteritis can be distinguished from necro-
tizing arteritis by the heavy mononuclear infiltrate within and
around the artely. Regrettably, many pathologists still do not
separate these lesions, regarding all "vascular rejection" as pre-
dominately humoral. Cellular arteritis has a much better rate of
reversal than does necrotizing arteritis (61% versus 29% one-year
graft survival) [19], which alone justifies their separation.
In most cases of acute cellular rejection, the glomeruli are
spared or show minor changes, typically a few scattered mononu-
clear cells (T-cells and monocytes) and occasionally segmental
endothelial damage [22, 24, 57]. In a minority of cases, a severe,
diffuse form of glomerular injury is evident and dominates the
histologic pattern. In 1981 our transplant pathology group drew
attention to a distinctive, acute allograft glomerulopathy, charac-
terized by hypercellularity, injury and enlargement of endothelial
cells, infiltration of glomeruli by mononuclear cells, and webs of
periodic acid Schiff (PAS)-positive material [58]. The glomeruli
contain numerous CD3 and CD8 T-cells and monocytes [24,
s1 The lymphocytes have an activated phenotype, as judged by
the presence of IL-2 receptor and HLA-DR. The glomeruli have
increased staining for HLA class-I antigens [24]. Immunofluores-
cent examination discloses fibrin and scant immunoglobulin and
complement deposits in glomeruli. This severe form of glomeru-
lopathy has been observed in 4% to 7% of biopsies taken for
allograft dysfunction, typically one to four months after transplan-
tation [58, 60—62]. Elevated serum levels of erythropoietin have
been associated with acute glomerulopathy, in contrast to lower
levels in tubulitis [631. Acute allograft glomerulopathy is believed
to be an unusual variant of cellular rejection, sometimes pro-
moted by cytomegalovirus infection. T-cells, not antibodies, are
regularly detected in glomeruli immunohistochemically [24, 59]
and OKT3 can reverse the lesion [64]. For unknown reasons,
rejection becomes focused on glomerular components; florid
glomerulopathy can occur with little interstitial inflammation,
although cellular endarteritis is common.
Certain pathologic features of acute rejection have prognostic
significance either individually or in combination. In the pre-CsA
era, only 10% of kidneys with either necrotizing arteritis, acute
glomerular lesion, or interstitial hemorrhage remained functional
at one year [65]. Others have confirmed the importance of these
lesions [19, 21, 66]; for example, interstitial hemorrhage correlates
with the later development of chronic progressive rejection, but
acute cellular rejection does not [66]. Infarction or glomerular or
arterial thrombi in the first 60 days is a reliable harbinger of graft
loss within a year [67]. Interstitial fibrosis in patients with acute
rejection is predictive of a poorer response to OKT3 therapy [20].
Graft survival at one year is not worse for grafts with cellular
arteritis than for those with tubulo-interstitial rejection without
cellular arteritis in the largest series (61% versus 64%) [19].
However, two studies suggest that the interstitial component is
more responsive to OKT3. The reversibility (75% versus 62%)
[201 and graft survival at one year (75% versus 58%) [53] are
higher after OKT3 treatment of acute cellular rejection without
endarteritis than in patients with endarteritis. The series are too
small for the differences to be statistically significant, and the
prognostic implication of cellular arteritis, beyond that of inter-
stitial rejection alone, remains uncertain. What is clear is that two
other types of vascular lesions, necrotizing arteritis and chronic
intimal proliferation, are much more ominous (29% and 10%
one-year graft survival, respectively) [19].
The intensity of the interstitial infiltrate has no correlation with
the rejection outcome [20, 21]. For this reason, we do not grade
the rejection based on the extent of the infiltrate. Similarly, the
number of CD3 or CD2 cells in the interstitial infiltrate
correlates with the presence, but not the prognosis, of rejection [3,
22, 68]. The relative proportion of CD8 cells correlates with a
poorer response to immunosuppressive therapy [22—24]. By mu!-
tivariate analysis, the diffuse cortical CD8 infiltrate was associ-
ated with graft loss within the 10 weeks, with a relative risk factor
of 46 (excluding cases with vascular involvement) [23]. The reason
for this is not clear; the CD8 might be resistant to the immuno-
suppressive drugs, or it might mediate more severe injury. Others
find no correlation with subsets and prognosis [20]. Eosinophil-
rich infiltrates are associated with graft loss, but these infiltrates
have little predictive value [32].
Acute glomerulopathy has a poor prognosis [58]; 67% of
allografts were lost in our combined series of 21 grafts [24, 58].
Graft loss correlates with the number of CD8 intraglomerular
cells but not with the CD4 cells [24]. Even in cases without overt
glomerulopathy, intraglomerular CD8 T-eells [22, 241 and
monocytes [571 correlate with subsequent graft loss. Glomerular
endothelial swelling also correlates with the later development of
chronic progressive rejection [66]. In contrast to tubulo-interstitial
rejection, the prognosis of the glomerulopathy is inversely related
to the intensity of the interstitial infiltrate of CD8 cells.
Lesions that resemble acute cellular rejection. Herpesvirus 1 (or
2) rarely causes an interstitial nephritis in renal allografts [69].
Nuclear clearing, necrosis and inclusions in tubular cells, and
occasional multinucleated cells suggest a viral infection by light
microscopy. The infiltrate is rich in neutrophils and has a mild
mononuclear component. Immunoperoxidase stains for herpes
antigens type 1 and 2 are strongly positive. Since herpes simplex
infections typically occur in the first month after transplantation,
some cases are probably misdiagnosed as rejection. Screening
biopsies with anti-viral antibodies should identify such cases.
Cytomegalovirus (CMV) rarely causes interstitial nephritis in
allografts, although CMV viruria commonly occurs. Recognition
of the cytopathic change is generally easy; however, the presence
of the virus is not sufficient to establish it as the cause of renal
dysfunction. Viral inclusions and CMV antigens occasionally have
been found in glomerular and peritubular capillary endothelium
and tubular epithelium by immunoperoxidase or by in-situ hybrid-
ization in asymptomatic patients with viruria [70].
Adenovirus can cause a severe necrotizing hemorrhagic inter-
stitial nephritis and renal failure in immunocompromised patients
[71]. Tubular cells have intranuclear inclusions with a distinct halo
surrounded by a ring of marginated chromatin (Cowdiy A) and
smudged nuclei. Adenovirus antigens were demonstrated in tu-
bular cells, which contain intranuclear crystalline arrays of 75—80
nm viral particles. Urine cultures were positive for adenovirus in
all 5 cases tested; 80% were type 11. We have rarely recognized
adenovirus infection in renal allografts, and we probably have
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missed others. The clues that lead to the diagnosis are the
glassy-appearing nuclear smudging, with more extensive tubular
necrosis and less extensive interstitial infiltrate than in typical
graft rejection. The bladder typically has hemorrhagic cystitis and
the prostate also can be infected. The diagnosis is established by
immunoperoxidase stains for viral antigen.
Drug-induced acute interstitial nephritis is among the more
difficult diagnoses to distinguish from acute cellular rejection in a
renal allograft. Both are characterized by an intense mononuclear
interstitial infiltrate and tubulitis, and both have variable numbers
of eosinophils. Acute rejection occasionally has a prominent
eosinophilic infiltrate; conversely, drug-induced interstitial ne-
phritis can have no eosinophils, especially when due to nonsteroi-
dal anti-inflammatory drugs. Endothelialitis is unequivocal evi-
dence of rejection. Strong, but perhaps not so absolute, evidence
for a drug-induced cause is the invasion of multiple tubules by
eosinophils. We have been perplexed by this differential, but we
have made the diagnosis correctly with these criteria in a few
patients taking prophylactic trimethoprim-sulfamethoxazole.
A dense mononuclear infiltrate of lymphoblasts due to lym-
phoma can cause renal failure [72], which in the renal allograft
can easily be confused with acute rejection. Both in rejection and
lymphoma the mononuclear cells have enlarged nuclei with
nucleoli and mitoses. Tubulitis is not a reliable sign, as it can occur
with lymphomatous infiltration. The diagnosis is not generally
difficult once the possibility has been raised. The L26 antibody to
CD2O reacts in formalin-fixed paraffin sections and is particularly
helpful if positive, because rejection does not have a predomi-
nance of B-cells. If the cells have a monomorphic surface pheno-
type, the diagnosis is confirmed; however, immunoperoxidase
stains may show polyclonal light chains in lymphoproliferative
disease.
Renal biopsies in patients with stable serum creatinine concen-
trations can demonstrate a mononuclear interstitial infiltrate,
especially in biopsies performed within the first four weeks; the
infiltrate occupies less than 10% of the cortex in patients taking
CsA at 3 weeks, and somewhat more for those not taking CsA [68,
73, 74]. One feature not found in stable grafts is acute cellular
arteritis [73]. This feature is helpful in making the diagnosis of
rejection when present, but its absence does not exclude rejection.
One of the most striking examples was the single "stable" patient
who had endothelialitis in a protocol biopsy (that is, the patient
had no clinical indication for a biopsy) only to develop acute
rejection a few days later [75]. A "subclinical allograft" infiltrate
has practical and theoretical implications. Clearly the presence of
an interstitial infiltrate alone within the first few months is not
sufficient evidence to diagnose rejection (or to exclude CsA
toxicity). We have seen focal infiltrates (5% of cortex) even in late
biopsy specimens from allografts in tolerant monkeys [761.These
"normal" allograft residents might contribute to graft acceptance.
Alternatively, the infiltrate might mediate subclinical injury, as
suggested by the observation that patients who had the least
infiltrate in sequential routine biopsies had the best graft function
at 12 months [77]. In any case, it is our strong recommendation
that clinical trials of new immunosuppressive drugs include rou-
tine biopsies at appropriate intervals to assess subclinical injury.
Chronic allograft rejection. The clinical features of chronic
rejection are a slowly rising serum creatinine concentration often
accompanied by increasing proteinuria and hypertension. Graft
function can decline gradually over a period of months to years,
with or without episodes of acute rejection. The rate of graft loss
is steady after the initial three to six months, with a "half-life" of
7.2 years for cadaver donor grafts, 10.8 years for parent-to-child
grafts, and 26.9 years for grafts from HLA-identical siblings [78].
The rate of long-term loss has not changed appreciably in the last
decade, despite considerable improvements in the one-year sur-
vival rate. Biopsy specimens from patients with chronic allograft
rejection show arterial iritimal fibrosis, glomerular mesangial
expansion and GBM thickening, tubular atrophy, and interstitial
fibrosis, in varied degrees and combinations. The vascular and
glomerular lesions are the most distinctive and are the prime
morphologic criteria of chronic rejection.
The arteries show pronounced fibrous intimal thickening with
myointimal cells, collagen fibrils, focal calcification, a variable
infiltrate of T-cells (often subendothelial) and lipid-filled, foamy
macrophages disposed characteristically against the external elas-
tica, which is duplicated and disrupted. The adventitia also often
has an infiltrate of mononuclear cells, sometimes invading and
destroying the outer media. The inflammatory features and the
foamy macrophages (if present) distinguish this lesion from
hypertensive intimal thickening. Hyaline change in the outer
media and isolated myocyte degeneration are not features of
rejection, in contrast to CsA toxicity. Experimental models [79]
have indicated that the lesions are due to a response to alloanti-
gens; class-I, -II, or non-MHC antigens are sufficient to induce
this response. Either antibody or T-cells can incite the intimal
fibrosis. The pathogenesis is likely to involve adhesion molecules
(for example, ICAM-1/LFA-1) and cytokines (for example,
IFNy).
The glomeruli have an increase in mesangial cells and matrix
and thickening and duplication of the GBM, with various degrees
of scarring and adhesions. One study of 123 renal allografts found
that after one year, almost all had adhesion of the tip of the
glomerular tuft to the origin of the tubule, the so-called "glomer-
ular tip lesion" found in some non-transplant patients with
nephrotic syndrome [80]. Foot process effacement, focal mesan-
gial cell interposition, and mesangiolysis also can be present [81].
Endothelial cell "dedifferentiation" is often evident, as manifested
by a loss of the normal fenestrations. Loss of this normal
differentiated structure of glomerular endothelial cells should
markedly restrict bulk water flow through the capillary wall and
should decrease filtration, Immunofluorescent examination shows
segmental or granular deposits of immunoglobulin (typically 1gM
and IgG, rarely IgA), C3, and sometimes fibrin in the capillary
wall and in the mesangium. This lesion has been shown to derive
from acute allograft glomerulopathy in a few cases [58, 62].
Extensive crescents, diffuse granular or linear deposits of IgG, or
subepithelial deposits are unusual and suggest recurrent or de-
novo glomerulonephritis.
Recent studies have demonstrated a chronic lesion in the
peritubular capillaries, consisting of splitting and multi-layered
duplication of the basement membrane, analogous to and corre-
lated with the chronic glomerular changes [82]. Thus the common
theme in chronic rejection is endothelial damage at the level of
the arteries, glomeruli, and peritubular capillaries. The microvas-
cular endothelium remains of donor origin; it expresses donor
antigen even after 25 years and thus can always be a potential
target of an alloresponse [83].
The long-term survival of grafts correlates highly with the
"chronic rejection score," combining the severity of the interstitial
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fibrosis, tubular atrophy, arterial intimal thickening, glomerular
sclerosis, mesangial expansion, and basement membrane duplica-
tion [66]. Similarly, the "chronic graft damage score" (measuring
intimal and interstitial fibrosis, tubular atrophy, lymphoid infil-
trates, and mesangial expansion) in routine biopsies at six months
also correlated with subsequent graft loss [84]. In a study of 128
functional allografts biopsied according to protocol at two years, a
high percentage of chronic lesions were seen: interstitial fibrosis
(62%), tubular atrophy (64%), intimal proliferation (36%), and
glomerular sclerosis (43%) [851. Although these changes were
mostly mild, they all correlated with progressive loss of graft
function. Interstitial fibrosis is a more reliable indicator of loss of
graft function at  10 years than is intimal fibrosis [66, 861.
Superimposed acute rejection is indicated by edema, tubular
invasion, or acute vascular lesions; the diagnosis follows the same
criteria for acute rejection alone, although tubulitis in atrophic
tubules has no diagnostic significance. A combination of tubulitis,
acute tubular necrosis, and an infiltrate predominantly of plasma
cells in 22 patients at 2 to 81 months post transplant was
associated with acute renal failure; a common cause other than
rejection was not identified, and graft loss occurred within six
months in 70% [87].
De-novo glomerulonephritis
Patients without previous glomerular disease occasionally de-
velop lesions in the allograft that resemble a primary glomerular
disease, rather than the usual chronic allograft glomerulopathy.
While some are no doubt coincidental, at least two are related to
the allograft response. The frequency of membranous glomerulo-
nephritis (MGN) in transplant biopsies is 2% [88]. Most cases of
MGN (83% to 90%) in renal allografts are due to de-novo disease
rather than to recurrence [881. No risk factors have been identified
(for example, HLA matching or specific infections), except the
duration of the graft (the prevalence rises to 8.3% after 8 years
[88]). The average time of appearance is five years after trans-
plantation but has been reported as early as two months. The
disease does not measurably shorten graft survival; the only graft
loss attributed to MGN was associated with renal vein thrombosis
[88]. As many as 20% to 30% of patients have no proteinuria,
even on long followup [89]. The deposits in de-novo MGN are
smaller than in idiopathic MGN of non-transplanted kidneys,
typically less than the width of a podocyte, and they have only
minor "spikes." De-novo MGN is probably a form of antibody-
mediated rejection directed at minor histocompatibility antigen(s)
in the glomerulus, presumably on the podocyte. De-novo MGN
occurs in grafts from HLA-identical, living-related donors [90]
and in kidneys from MHC-identical rats [911. De-novo MGN has
been described in bone marrow recipients [92], but not to my
knowledge in recipients of other organ allografts. These facts are
consistent with the view that the alloantigen must be expressed in
the glomerulus.
Anti-GBM nephritis has been reported in grafts transplanted
into patients who have Alport's syndrome. The common form of
Alport's syndrome is characterized by a genetic defect in the u5
chain of type-TV collagen encoded on the X chromosome; this
defect prevents the glomerular expression of the a5 chain and
indirectly the a3 (IV) chain, the usual target of anti-GBM
nephritis. Alport's patients thus can form alloaritibodies to the
normal allograft GBM. The antibodies are expected to be directed
largely at the aS chain, rather than the a3 chain. Although
dramatic, the development of anti-GBM nephritis is rare, and the
overall experience with transplantation in hereditary nephritis is
good. Among 30 patients, none developed nephritis, although one
had transient deposition of linear IgG in glomeruli [93]. The
five-year graft survival of these 30 patients was equal to that of
non-Alport's recipients. In a large series of 34 Alport's patients,
linear glomerular lgG deposits developed in 15%; however, none
had overt glomerular injury or circulating antibodies [94]. It is
possible that the minority with severe injury formed anti-a3
antibodies, or that the genetic defect is different.
Focal glomerular sclerosis (FGS) occasionally develops in al-
lografts in patients in whom FGS is not the primary disease. This
lesion has been noted especially in pediatric kidneys (under age 3
years) transplanted into adults [95]. The pathophysiologic mech-
anism appears to be hyperfiltration injury. In addition, we recently
have seen several examples of the collapsing variant of FGS in
allografts (the present case and Meehan 5, et al, unpublished
observation). The mechanism is unknown, and all patients were
HIV negative. An infectious agent has been postulated [96]. The
afferent arteriolar vasoconstriction produced by GsA might con-
tribute to the pathogenesis. No specific therapy has been prom-
ising, and the collapsing variant typically progresses to renal
failure in less than one year [96].
Recurrent renal disease
Recurrent disease is a small but significant cause of allograft
failure, estimated to affect 1% to 5% of recipients [97]. The
frequency and clinical significance of recurrence varies with the
disease [97—99]; the disease that most commonly causes graft loss
is focal sclerosis; the other diseases that frequently recur often
have a benign course. Cyclosporine does not appreciably affect the
recurrence rate [99]. Table 3 summarizes data from the larger
series (to minimize the overestimation inherent in individual case
reports) with adequate documentation [1]. Obviously the diagno-
sis of recurrence requires accurate classification of the original
disease and lesions that clearly differ from chronic allograft
glomerulopathy.
Cyclosporine A toxicity
Cyclosporine has greatly improved graft survival since its clin-
ical introduction in the early 1980s, but its major problem remains
nephrotoxicity. In one series, 38% (90/240) of renal allograft
biopsies performed for graft dysfunction showed CsA toxicity [4].
Cyclosporine binds to the "cyclophilins," a family of peptidyl-
prolyl cis-trans isomerases [100]. These enzymes ("foldases") are
believed to confer conformational changes as proteins are synthe-
sized. The CsA-cyclophilin complex inhibits calcineurin, a phos-
phatase activated by calmodulin/Ca4. Calcineurin is needed to
activate nuclear factor of activated T-cells (NFAT), a transcrip-
tion factor for cytokines; phosphate removal promotes transloca-
tion of NFAT to the nucleus. The dramatic immunosuppressive
effect of CsA is thus explained by inhibition of lymphokine
production by T-lymphocytes (IL-2, IL-4, IFNy, and others).
Cyclophilins are widely distributed and are present in virtually
all cells. Four distinct cyclophilins with 60% to 70% sequence
homology have been identified. Cyclophilin A (the first to be
purified) is a cytoplasmic protein ubiquitous in all organs. The
principal site of immunoreactivity for cyclophilin A in the human
kidney is the proximal tubule; other positive cells are vascular
smooth muscle [101]. Cyclophilin C is limited to the kidney and
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Table 3. Recurrent glomerular disease°
Recurrence % Recur % Lost # Cases
Usual
Dense-deposit disease 90 15 75
Common
IgA nephropathy 38 3 74
Henoch-Schonlein purpura 38 >0 26
Focal glomerular
sclerosis, 10 34 10 198
Hemolytic-uremic syndrome 27 16 44
Membranoproliferative
glomerulonephritis, type 1 27 9 153
Amyloidosis 27 0 11
Membranous
glomerulonephritis 17 3 35
Idiopathic crescentic
glomerulonephritis 15 8 48
Occasional
Anti-GBM disease 5 5 22
Wegener's granulomatosis 7 0 14
Systemic lupus
erythematosus 5 2 42
Diabetes mellitus (estimated) <1 0 >1000
No recurrence described
"Classical" HUS 0 0 18
Hereditary nephritis
(Alport's syndrome) 0 0 64
Focal glomerular
sclerosis, 2° 0 0 15
Congenital nephrotic
syndrome 0 0 17
Postinfectious
glomerulonephritis 0 0 3
Reprinted with permission from Raven Press [1].
activated T-cell lines. Thus it might be a target for the nephrotoxic
effects of CsA [102]. Toxicity correlates imperfectly with blood or
serum levels.
Acute nephrotoxicity usually presents as nonoliguric renal
failure with sodium retention, hyperkalemia, and hyperchioremic
hypobicarbonatemia. Hypertension is uncommon and fever is
highly unusual [1031. Cyclosporine alters the metabolism of
arachidonate [103], shifting the balance towards vasoconstriction
and thrombosis (increased TxA2) and decreased vasodilation and
anti-thrombosis (decreased Pg12 and prostacyclin).
The acute tubular lesions in humans are similar to those
described in rats [104]. The proximal tubules show the greatest
morphologic changes: isometric vacuolization, giant mitochon-
dna, enlarged multiple lysosomes, and microcalcification. Isomet-
ric vacuolization predominates in the straight portion of the
proximal tubule [105], although we have seen it in the convoluted
portion. The vacuoles contain aqueous fluid rather than lipid, and
are indistinguishable from those caused by osmotic diuretics.
Necrotic cells are uncommon, but the dystrophic calcification
presumably is a remnant of a necrotic epithelial cell. The diagno-
sis of cyclosporinc toxicity is difficult because none of these
features is pathognomonic for CsA, and these features can occur
in other conditions, notably acute ischemic renal failure. Further-
more, CsA toxicity can occur in the absence of morphologic
changes. Difficulty arises in the distinction between rejection and
CsA toxicity, and the possibility that they can co-exist. Interstitial
infiltrates are minimal in autologous kidneys with ncphrotoxicity
Table 4. Differential between acute cellular rejection
and acute CsA toxicity
Rejection CsA toxicity
Interstitium
Intersitial Moderate-marked Absent-mild
infiltrate
Tubules
Tubular injury Usual Usual
Vacuoles Occasional Common
Tubulitis Prominent Minimal
Arterioles
Endarteritis Common Absent
Smooth muscle Absent Sometimes present
degeneration
Mucoid intimal Absent Sometimes present (HUS)
thickening with
red cells
[104], but are common in early allografts [73], and only have
differential value if they are minimal [52, 106, 107]. Interstitial
edema is typically slight in toxicity [52, 105], but it also is an
unreliable discriminator [108], as is the invasion of tubules by
lymphocytes [52, 107]. Sibley and colleagues noted that in CsA
toxicity, mononuclear cells tend to remain in the peritubular
capillaries rather than infiltrate the interstitium, but this finding
has limited differential value [52]. In my experience and that of
others [52, 106], the only unequivocal evidence for rejection is
acute cellular arteritis, which is not found in CsA toxicity alone
(<2%) (Table 4).
Mihatsch et al have described a spectrum of acute and chronic
arteriolopathy, ranging from acute, focal myocyte necrosis and
mucoid intimal thickening to indolent nodular hyaline deposits
[1051. The characteristic features are individual smooth muscle
cell degeneration, vacuolization, necrosis, and graft loss. A recent
report notes that immunohistochemical stains for renin are re-
duced in chronic CsA arteriopathy; the authors speculate that the
renin-producing smooth muscle cells might be the specific target
of the CsA injury [109]. The myocytes are replaced by hyaline
deposits, which classically appear in a beaded pattern in the
media; the usual hyaline deposits in hypertension or diabetes are
subendothelial. The endothelial cells may be vacuolated. The
vessels in early biopsies show deposits of 1gM, C3, and fibrin.
Later biopsies show progressive scarring of arterioles, intimal
fibrosis, and segmental glomerular obsolescence. None of the
vascular lesions is unique. However, focal myocyte necrosis in the
media of small arteries, in the absence of iritimal changes, is a
reliable indicator of CsA toxicity [106, 108]. These changes are
probably related to the more dramatic endothelial/smooth muscle
damage that results in the hemolytic-uremic syndrome.
Cyclosporine arteriopathy was held responsible in one study
from the mid-1980s for 40% of all renal allografts that failed,
(overall, 7.5% of 200 cadaver grafts) [110]. The arteriopathy may
be less common with the current lower dose regimens, but it is still
seen. Reduction of CsA dosage is followed by morphologic
resolution in about 50% of patients, as judged by repeat biopsy
after 6 to 18 months [111]. The pathogenesis is obscure. Arterial
damage is not elicited by CsA in normal animals unless combined
with other factors that cause vascular injury.
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Hemolytic-uremic syndrome (HUS) is the clinical manifesta-
tion of the extreme form of the arteriopathy. First reported in
bone marrow recipients [112], HUS due to CsA has subsequently
been noted in renal allografts [113]. The patients develop acute
renal failure, thrombocytopenia (due to platelet consumption in
the kidney), microangiopathic anemia, and hyperbilirubinemia.
The syndrome occurs in the first two weeks with the rapid onset of
anuria, or with a slower loss of function one to five months post
transplant [1101. The presence of intravascular hemolysis is help-
ful in the differential diagnosis, as severe hemolysis is unusual in
graft rejection. Hemolytic-uremic syndrome occurs despite cur-
rent regimens of CsA administration, even with careful attention
to blood CsA levels.
The small arteries and arterioles have mucoid intimal thicken-
ing, with extravasated red cells and fragments, necrosis and
thrombi of arterioles, and glomerular thrombi. This differs from
rejection with necrotizing arteritis, described in the pre-CsA
literature as accelerated rejection. The pathologic changes of CsA
are not distinguishable by current techniques from those of the
idiopathic hemolytic-uremic syndrome. Whether CsA increases
the frequency of recurrence is not proved: de-novo HUS arose in
0.5% of 225 renal allograft patients who did not receive CsA and
in none of 358 patients taking CsA [99]. The prognosis of the
acute CsA vasculopathy is poor; in one series of 16 renal allograft
recipients, 75% lost their graft [1031; in another, the loss rate was
94% (15 of 16), even with the discontinuance of CsA [110]. It has
been reported that FK506 can be tolerated by patients who have
had to stop taking CsA because of HUS [114].
Loss of renal function in patients taking CsA for more than one
year was clearly demonstrated in cardiac allograft recipients [115].
Biopsies show interstitial fibrosis and tubular atrophy, with a
sparse infiltrate. Band-like ("striped") zones of fibrosis, said by
some to be characteristic of CsA [52, 108], suggest a vascular
mechanism or damage to the medullary rays. Despite the catchy
term "striped fibrosis," the chronic scarring pattern is not suffi-
ciently distinctive to be reliably distinguished from that commonly
found in long-term renal allografts not exposed to CsA therapy.
The lesions also have been widely documented in native kidneys in
patients taking CsA. Several studies have shown that interstitial
fibrosis develops within one year in patients treated with <5
mg/day CsA for psoriasis and correlates closely with a reduced
GFR (12% on average) [116]. Arteriolopathy was evident in the
two-year biopsy [117]. Similarly, interstitial fibrosis and tubular
atrophy were evident in 25% of 40 type-I diabetic patients treated
with CsA for 6 to 29 months [118]. The pathogenesis of interstitial
fibrosis and tubular atrophy is uncertain, but it is clearly attribut-
able to CsA, as it occurs in CsA-treated autografts in rats [119]. In
a careful study, nifedipine, a calcium-channel blocker, has shown
some promise in reducing the interstitial lesions in renal trans-
plant allografts [120].
The clinical experience with tacrolimus (FK506) is limited, but
so far FK506 has shown nephrotoxicity similar to CsA, including
reversible acute renal failure, hemolytic-uremic syndrome, and
chronic lesions of arteriolar hyalinosis and striped fibrosis. Medial
vacuolization of renal arterioles has been noted in 80% of
patients; decreasing the FK506 dose reverses the process [121].
The thrombotic angiopathy is reversible upon discontinuance of
the FKSO6 [122]. Long-term changes are similar to those of CsA,
with "striped fibrosis" in 35% at a mean of 200 days post
transplant and hyalinosis in 40% [122]. The patterns are not yet
distinguishable from those of CsA toxicity, although focal glomer-
ular sclerosis was noted in 25% of patients taking FK506, but not
in 13 patients randomized to receive GsA [122]. Let me add one
footnote. The renal transplant patient receives a variety of drugs
with potential renal toxicity, such as OKT3, which can produce
thrombotic angiopathy [123], and acyclovir [124]. All these drugs
are relevant to the differential diagnosis of unexplained azotemia.
Alternative diagnostic techniques
For some time investigators have sought a less invasive method
than biopsy of diagnosing intragraft events. These methods have
included analysis of peripheral T-cells, activation markers in
blood lymphocytes, and serum and urine levels of cytokines. None
of these approaches has yet become established clinically, primar-
ily because of non-specificity (overlap with changes in these
parameters due to viral infections) and lack of sensitivity. If I had
to bet, I would put my money on urine tests [125], especially those
that can be done by the patient at home, since urine represents a
sample of "graft juice."
Fine-needle aspiration (FNA) of renal allografts has been
investigated extensively by Hayiy, von Willebrand, and colleagues
[126]. The key advantage is that the aspirates can be obtained
frequently (even daily) with little or no risk, permitting assessment
of the rate of change of the inflammation and response to therapy.
The major disadvantages are that vessels cannot be evaluated and
that the spatial relationships of cells are lost. The technique is not
adequate for assessing chronic changes, glomerular disease, or
vascular injury. The technique, now performed in many centers,
continues to be refined. The addition of monoclonal antibodies
and PCR permits more precise identification of cell types and
their function. For example, HLA-DR and interferon gamma
expression characterize acute rejection [127].
Fine-needle aspiration probably will find a niche in clinical
management, although it is unlikely to replace the biopsy. In a
randomized prospective trial, the sensitivity of biopsy was superior
to FNA (75% versus 59%) for rejection as defined by subsequent
clinical course [1281. Thus, for the foreseeable future, clinical
management will rely in a critical fashion on the renal biopsy.
Questions and answers
JOHN T. HARRINOTON (Dean ad Interim, Tufts University School
of Medicine, Boston, Massachusetts): Dr. Colvin, let me begin by
asking some basic questions about the interpretation of the
transplant kidney biopsy. What are the data demonstrating that
the renal biopsy in the transplant patient is representative of the
whole kidney? Specifically, do we have information comparing
such renal biopsies with pathologic studies of the whole kidney in
patients who lost their kidney in the few days after the biopsy?
This approach was used some 30—40 years ago to establish the
validity of renal biopsy in the non-transplant patient. In effect, im
asking, how much tissue do we need, and what's the evidence for
your conclusion?
DR. C0LvIN: The best recent publication on this is by Sorof et
al, using paired biopsy cores [129]. In that study, a false-negative
rate of 10.5% for clinically treatable rejection was found with a
single core. That percentage is similar to the results of the CCTT
study (unpublished), and it is the reason why we recommend
obtaining two cores. This approach reduces the false-negative rate
to 1%.
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DR. NICOLAOS E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): I'd like you to
expand on your assessment of the utility of fine-needle aspiration
biopsy.
DR. C0LvIN: There's no question that in pathology, as else-
where in medicine, we are trying to do more with less: use
less-invasive procedures at less cost. Fine-needle aspiration fits
those criteria, so the question is whether FNA gives information
good enough to allow one to decide whether to intervene. As
things stand, in my opinion, it's not a good enough guide by itself
to institute therapy. Fine-needle aspiration is now being combined
with molecular studies by PCR. I would not be surprised if
something clinically useful will be developed from these efforts.
DR. AJAY SINGI-I (Division of Nephrology, New England Medical
Center): Your comments about the characteristics of the T-cell
infiltrate in rejection reminded me of an interesting issue in the
autoimmune renal disease literature, namely the balance of Thi
to Th2 cells in the T-cell response. As you know, Thi cells, which
produce IL-2 and IFN-y, engage in cell-mediated immunity and
arguably are pathogenetic, whereas Th2 cells producing IL-4, 11-5,
and IL-b seem to resist pathogenicity [130]. Studies by Nielsen
and co-workers on murine anti-TBM disease [131, 132], and
evidence from the leishmaniasis literature [133, 1341, seem to
support the importance of the two Th limbs in disease exacerba-
tion and protection, respectively. Could you update us on whether
investigators have examined Th subsets in rejection? Have any
studies tried to correlate the level of imbalance with the severity
of rejection?
DR. C0LvIN: The cytokine data indicate that acute rejection is
primarily a Thi phenomenon. We know little about the nature of
the infiltrate in an accepted graft. The best information is from
Mottram et al, who showed in a rat model that the cytokine profile
shifted to Th2 in long-term accepted grafts (IL-4 and IL-b) [135].
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): I wanted to ask you about acute and chronic
allograft glomerulopathy. In particular, what's the evidence that
these lesions are related to the rejection process itself? For
example, have they been observed in animal models of transplan-
tation? Do these same lesions occur in native kidneys?
DR. C0LvIN: The answer to both questions is no. I know of no
animal model, and it is not seen in native kidneys. Perhaps the
closest lesion is hemolytic-uremic syndrome/thrombotic microan-
giography, which can have similar GBM duplication and accumu-
lation of cellular debris. The two probably share a common
element of injury to the glomerular endothelium. I believe that
acute allograft glomerulopathy is part of rejection because it is
associated with the same vascular lesions. Other arguments that
favor rejection are: (1) We and others have not found CMV in the
lesions; (2) T-cells are present; and (3) Some cases respond to
anti-T-cell antibodies. To prove that it is a rejection process, one
would need to isolate the T-cells from the glomerulus and
demonstrate that they react to alloantigens.
DR. ANDREW KING (Division of Nephrology, New England Med-
ical Center): You described glomerular changes of mild mesangi-
olysis and endothelial swelling in inflammatory cells. This pattern
brought to mind the pathologic findings of thrombotie microan-
giopathy. Do you think this is a rejection process or a cyclospor-
me-induced endothelial injury?
DR. CoIvTN: It can look like HUS. The morphologic differences
are the increased number of T-cells and decreased fibrin, corn-
pared with the usual thrombotic microangiopathy. It does arise in
patients not taking CsA.
DR. INA BHAN (Department of Pathology, Tufts University School
of Medicine): I have three questions. First, do you look at vessels
other than arteries and arterioles for endothelialitis? Second,
what is the role of frozen section in the evaluation of the
transplant biopsy? My third question is regarding the evaluation
of the subcapsular region of the cortex.
DR. C0LvIN: I only look at the arteries for endothelialitis.
Mononuclear cells normally emigrate through the venules and
capillaries, and their presence in those sites does not necessarily
denote an attack on the endothelium, but may be just a part of the
inflammatory process. Regarding your third question, not uncom-
monly a biopsy, especially after the graft has been in for a while,
has inflammation underneath the capsule. We always disregard
the first millimeter or so under the capsule as not being repre-
sentative of what's going on in the kidney. As to our use of frozen
sections, Michael Fredrickson in our histology laboratory has
developed rapid processing (2 hours) for permanent sections. The
histology is much better than a frozen section, and this is now our
routine way of handling Friday afternoon and weekend biopsies.
DII. HARRINGTON: You mentioned that you often saw vascular
lesions and stated that "acute vascular rejection" was present in
about 50% of cases. What specifically does 50% of cases refer to?
DR. C0LvIN: It refers to the half of biopsy specimens with
tubulointerstitial rejection.
DR. MADIAS: Is rejection or its severity a risk factor for the
development of de-novo membranous glomerulonephritis in the
graft?
DR. C0LvIN: No. The only risk factor I know of is duration of
the transplant.
DR. MARK E. WILLIAMS (New England Deaconess Hospital,
Boston, Massachusetts): One sometimes sees early in the treat-
ment of allograft rejection, a kidney that swells and a serum
creatinine that rises faster than one would have expected, and this
is attributed to the direct effects of the anti-rejection therapy.
Could a component of this response be a paradoxical effect of
immunosuppression?
DR. C0LvIN: What is probably occurring is the consequence of
lysis of the cells in the graft by the steroids or the OKT3.
DR. JULIA R. NEURINGER (Division of Nephrology, New England
Medical Center): Are you aware of any experimental data regard-
ing typing of non-HLA endothelial cell antigens? Do you think
that typing would be clinically useful?
DR. C0LvIN: Clearly, non-HLA antigens are important, as
judged by the occasionally severe rejection of HLA-identical
grafts [1]. Several endothelial/monocyte/platelet alloantigens have
been recently identified, for example, Naka on CD3b; Zwa and
PIA1 on GPIIIa-vitonectin receptor. Clinical correlations will be
needed to assess their practical relevance to transplantation.
DR. HARRINGTON: You mentioned that IL-8 is a potent chemo-
tactic agent for T-cells. What do we know about the interaction of
IL-8 and the adhesion molecules? How do they work together?
DR. C0LvIN: The interactions are complicated. IL-8 can in-
crease the expression of CDI8 integrins on the neutrophil surface
[136], but free IL-8 inhibits endothelial-neutrophil adhesion in
vitro [137].
Reprint requests to Dr. R. Colvin, Department of Pathology, Massachusetts
General Hospital, Boston, Massachusetts 02114, USA
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